All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Bookmark this article
On September 8, 2023, vididencel, an off-the-shelf, intradermal vaccine, received fast track designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with acute myeloid leukemia (AML) in complete remission (CR) with residual disease.1 Vididencel was also previously granted orphan drug designation for the treatment of patients with AML in the U.S. and Europe.1
This fast track designation is based on results from the phase II ADVANCE II trial (NCT03697707) assessing vididencel monotherapy as a maintenance therapy for patients with AML in CR following chemotherapy, but with measurable residual disease (MRD).1,2 Results demonstrated that vididencel has the potential to control MRD and induce durable relapse-free survival.1 Vididencel will also be evaluated in combination with oral azacitidine in an upcoming phase II trial.1
FDA lifts partial clinical hold on phase I/II TakeAim Leukemia trial of emavusertib in patients with AML and MDS
On July 6, 2023, the U.S. FDA lifted the partial clinical hold on the phase I/II TakeAim Leukemia trial of emavusertib, an orally...
The NOPHO-DB-SHIP consortium recommendations for supportive care in pediatric AML
A summary of recommendations published in Expert Review of Anticancer Therapy by Arad-Cohen, et al. They include general management of children and adolescent patients...
Subscribe to get the best content related to AML delivered to your inbox